Drug Profile
BI 1060469
Alternative Names: BI-1060469Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma in Germany (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma(In volunteers) in South Korea (PO, Tablet)
- 03 Sep 2016 Adverse events and pharmacokinetics data from two phase I trials in Healthy volunteers presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)